FDA Greenlights Zoryve Cream by Arcutis as Breakthrough Treatment for Atopic Dermatitis in All Ages

Tuesday, 9 July 2024, 21:14

Arcutis, a pharmaceutical company, achieves a milestone with FDA approval for Zoryve cream at 0.15% strength for treating atopic dermatitis in patients aged six years and above. The newly approved skin treatment offers hope for individuals suffering from this chronic skin condition. The approval marks a significant advancement in the pharmaceutical industry's efforts to address dermatological needs effectively.

Seeking Alpha — FDA Greenlights Zoryve Cream by Arcutis as Breakthrough Treatment for Atopic Dermatitis in All Ages

Arcutis Receives FDA Approval for Zoryve Cream

Arcutis (ARQT) announced today that the FDA has given the green light for its innovative Zoryve cream at a strength of 0.15%.

Breakthrough Treatment for Atopic Dermatitis

This milestone approval now allows patients aged six years and older to access this advanced treatment option for atopic dermatitis.

The approval underscores Arcutis' commitment to developing effective solutions for chronic skin conditions.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.